[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"chronic-prostatitis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:chronic-prostatitis":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,48,90,120,142],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100449064","eppic-easing-pelvic-pain-interventions-clinical-research-program-100449064",false,"NCT05127616","EPPIC: Easing Pelvic Pain Interventions Clinical Research Program","A Brief, Transdiagnostic Cognitive Behavioral Treatment for Urological Chronic Pelvic Pain Syndrome: Processes, Predictions, Outcomes","EPPIC","Inclusion Criteria:\n\n* Ages 18-70 years (inclusive)\n* Male or female\n* All genders, races, ethnic groups\n* MD-confirmed diagnosis of IC\u002FBPS or CP\u002FCPPS by study urologist or urogynecologist\n* Pelvic pain including uncomfortable sensations of pressure or discomfort that are not described as outright pain) of at least six months duration\n* Pelvic pain intensity of at least moderate severity (defined as 3 or greater on a 0-10 Numerical Rating Scale and causes life interference weekly and limit(s) participant's life or work-related activities, general activity level, and\u002For enjoyment of life) over the past 3 months.\n* Ability to understand and provide informed consent\n* Either not taking medications or if taking medications willing to refrain from starting new medications until after the initial 2-week pre-treatment baseline period ends unless medically necessary.\n* A minimum 6th grade reading level based on the Wide Range Achievement Test (WRAT 4)\n* Willing to be randomized to either CBT or Support\u002FEducation and to follow the protocol to which s\u002Fhe has been assigned\n* Willing to be contacted for follow up assessments at week 12 and 3, 6 months after treatment ends\n* Willing to attend sessions\n* Able to maintain symptom diaries and complete paper work\n* Access to telephone and computer or smartphone\n* Willing and able to provide adequate information for locator purposes\n\nExclusion Criteria: Urologic-Specific\n\n* Presence of a neurological condition (e.g., MS, Parkinson's disease, paraplegia) affecting the bladder\n* The presence of a symptomatic urethral stricture (males only)\n* History of cystitis caused by tuberculosis or radiation or chemotherapies\n* Participant has been diagnosed and treated for a pelvic-related malignancy (colon, bladder, prostate, ovarian, endometrial, uterine, testicular, penile, cervical, vaginal, or rectal cancer)\n\nExclusion Criteria: General\n\n* Participant has a medical condition(s) whose nature or severity (unstable, life threatening, etc.) would influence adversely the conduct of the clinical trial, confound interpretation of study results, and\u002For compromise volunteer safety and engagement with study demands.\n* Gross cognitive impairment, deafness, blindness, vision problems (severe), hearing problems (severe)\n* Has a major psychiatric disorder which would impede conduct of the clinical study. These clinical disorders would include but are not limited to major depression with a high risk of suicidal behavior (i.e. intent or plan), current or recent (within the past 3 months) history of alcohol or substance abuse\u002Fdependence, a lifetime history of schizophrenia or schizoaffective disorder; or organic mental disorder\n* Current involvement in psychotherapy directed specifically toward relief of urological symptoms\n* Schedule does not permit participation in clinic sessions or home practice including plans to move out of the area, lack of reliable transportation, etc.\n* Characteristics related to inability to complete the study protocol\n* Unable to read or fluently speak English\n* Inability to complete screening visits\n* Inaccessible for interventions and\u002For follow up evaluations","ALL","18 Years","70 Years",{"count":21,"type":22},240,"ESTIMATED","INTERVENTIONAL",[25],"NA","The EPPIC (Easing Pelvic Pain Interventions Clinical Research Program) study evaluates an ultra-brief, 4 session cognitive behavioral pain treatment transdiagnostic in design for urologic chronic pain syndrome (UCPPS) with clinical and practical advantages over existing behavioral therapies whose length and focus limits their adoption by clinicians and coverage for mechanistically similar comorbidities. A theoretically informed, practical, empirically grounded approach will systematically unpack CBT's working mechanisms, clarify for whom it works, ease dissemination, appeal to patients, providers, payers, and policy makers in the COVID-19 era favoring low resource intensity treatments, and reduce cost and inefficiencies associated with high intensity therapies whose complexity, length, and scarcity restricts uptake and impact.",[28,29,30,31,32,33,34],"Urologic Chronic Pelvic Pain Syndrome (UCPPS)","Interstitial Cystitis","Bladder Pain Syndrome","Chronic Prostatitis","Chronic Pain","Chronic Pelvic Pain Syndrome","Chronic Overlapping Pain Disorders","RECRUITING","2026-01-22",{"date":38,"type":39},"2026-01-26","ACTUAL",{"date":41,"type":39},"2022-08-10",{"date":43,"type":22},"2028-07-31",{"name":45,"class":46},"State University of New York at Buffalo","OTHER",3,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":23,"phases":57,"briefSummary":58,"conditions":59,"keywords":68,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":83,"completionDateStruct":85,"leadSponsor":87,"locationsCount":89},"100539118","pain-type-and-interstitial-cystitisbladder-pain-syndrome-treatment-100539118","NCT06299683","Pain Type and Interstitial Cystitis\u002FBladder Pain Syndrome Treatment","Mechanistic-Based Treatment of Interstitial Cystitis\u002FBladder Pain Syndrome","Inclusion Criteria:\n\n* 18 years of age or older;\n* Diagnosis of IC\u002FBPS as indicated by structured assessments;\n* Capable of giving written informed consent;\n* Able to enroll for the duration of the study period;\n\nExclusion Criteria:\n\n* Comorbid neurological conditions including spinal cord injury or systematic neurologic illnesses, or central nervous system diseases such as brain tumor or stroke;\n* Current or history of diagnosis of primary psychotic or major thought disorder within the past five years;\n* Hospitalization for psychiatric reasons other than suicidal ideation, homicidal ideation, and\u002For PTSD (within the past 5 years);\n* Psychiatric or behavioral conditions in which symptoms are unstable or severe (e.g. current delirium, mania, psychosis, active suicidal ideation, homicidal ideation, substance abuse dependency) reported within the past six months;\n* Non-English speaking;\n* Presenting symptoms at time of screening that would interfere with participation, specifically active suicidal ideation with intent to harm oneself or active delusional or psychotic thinking;\n* Difficulties or limitations communicating over the telephone or via teleconferencing systems;\n* Any planned life events that would interfere with participating in the key elements of the study;\n* Any major active medical issues that could preclude participation;\n* Currently pregnant;\n* Currently being treated for cancer;\n* Cancer-related pain;\n* Recently or actively participating in treatment similar to those being investigated (e.g. individual psychotherapy or pelvic floor pt).",{"count":56,"type":22},220,[25],"Interstitial cystitis\u002Fbladder pain syndrome (IC\u002FBPS) is a severe pain condition affecting 3-8 million people in the United States lacking treatments that work. Emotional suffering is common in IC\u002FBPS and known to make physical symptoms worse, and studies show patient sub-groups respond differently to treatment. Individuals with IC\u002FBPS have distinct subgroups, or \"phenotypes,\" largely characterized by the distribution of pain throughout the body. Supported by our preliminary evidence, the overall goal of this project is to assess how IC\u002FBPS phenotype may affect response to two different therapies often given without regard to patient phenotype, pelvic floor physical therapy (PT) and cognitive-behavioral therapy (CBT) for IC\u002FBPS.",[60,30,61,62,63,29,64,65,66,31,67],"Chronic Interstitial Cystitis","Painful Bladder Syndrome","Cystitis, Interstitial","Cystitis, Chronic Interstitial","Interstitial Cystitis, Chronic","Interstitial Cystitis (Chronic) With Hematuria","Interstitial Cystitis (Chronic) Without Hematuria","Chronic Prostatitis With Chronic Pelvic Pain Syndrome",[69,70,71,72,73,74,75,76,77,78,79],"interstitial cystitis","bladder pain syndrome","clinical trial","psychosocial intervention","pelvic pain","therapy","urological chronic pelvic pain syndrome","chronic prostatitis","self-management","cognitive behavioral therapy","pelvic floor physical therapy","2026-01-20",{"date":82,"type":39},"2026-01-21",{"date":84,"type":39},"2024-05-01",{"date":86,"type":22},"2028-04-04",{"name":88,"class":46},"Vanderbilt University Medical Center",1,{"id":91,"slug":92,"hasResults":11,"nctId":93,"briefTitle":94,"officialTitle":95,"acronym":96,"eligibilityCriteria":97,"healthyVolunteers":11,"sex":98,"minAge":99,"maxAge":4,"enrollmentInfo":100,"targetDuration":4,"studyType":23,"phases":102,"briefSummary":103,"conditions":104,"keywords":110,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":113,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":89},"100505998","efficacy-of-low-intensity-shockwave-vs-radial-wave-for-treatment-of-erectile-dysfunction-and-pelvic-pain-100505998","NCT05868668","Efficacy of Low-intensity Shockwave vs Radial Wave for Treatment of Erectile Dysfunction and Pelvic Pain","Randomized Controlled Trial of Focused Shockwave, Radial Wave, and Sham Therapy for Erectile Dysfunction and Focused Shockwave and Sham Therapy for Chronic Pelvic Pain Syndrome in Patients With and Without History of Prostate Cancer","Shockwave","Erectile Dysfunction Group (ED) Inclusion Criteria (ED): (all of the following)\n\n1. Cis-gendered heterosexual adult males18 years old\n2. Stable relationship of more than 3 months duration with currently willing sexual partner and desire for penetration.\n3. Mild to moderate organic erectile dysfunction (IIEF-EF score 11-25) in the last 3 months\n4. If ED responsive or partially responsive to current use of PDE5I, participant must be willing to discontinue PDE5I for 4 weeks prior to trial and remain off PDE5I for the duration of the study. Partially responsive ED is defined as inadequate response for desired sexual activity, or poorly maintained erection despite initially good response.\n5. Agreeable to attempt sexual intercourse at least 4 times per month for duration of study without being under the influence of alcohol or recreational drugs\n6. Morning total testosterone level over 300ng\u002FdL\n\nExclusion Criteria (ED):\n\n1. Nerve-injury related ED (\u002Fspinal cord injury, severe lumbosacral disorder (radiculopathy, spinal stenosis) or other neurological disease affecting erectile functions (e.g, multiple sclerosis, alzheimer's disease, parkinsons disease, amyotrophic lateral sclerosis)\n2. Untreated hypogonadism (morning total testosterone \\\u003C300 ng\u002FdL) or on androgen deprivation therapy in the last 12 months\n3. Predominately psychogenic ED based upon expert clinician opinion\n4. Peyronie's disease, palpable plaque or curvature\u002Fpenile anatomic abnormality that affects penetrative intercourse to any degree\n5. History of non-superficial penile surgery (e.g, penile prosthesis, penectomy, plication, grafting)\n6. History of penile injury or trauma (e.g, priapism, penile fracture)\n7. Use of intracavernosal injection for ED within the last year\n8. If diabetic, HbA1c 8% or higher within the past 12 months\n9. Known corporal veno-occlusive dysfunction based on prior Doppler penile ultrasound\n10. Current tobacco smoker, or has smoked in the past year\n11. Poorly controlled hyperlipidemia\n12. Poorly controlled hypertension\n13. Severe cardiac disease or history of myocardial infarction\n14. History of psychiatric disorder including bipolar disorder, current moderate or severe depression\n15. Patients currently using SSRI or psychotropic medication\n16. Severe ED based on IIEF-EF (score 10 or below)\n17. Current acute prostatitis\n\nChronic Pelvic Pain Syndrome Group:\n\nInclusion Criteria (CPPS): (all of the following)\n\n1. Adult males ≥18 years old\n2. Chronic pelvic pain not explained by concurrent urinary tract infections. urine)\n3. Willing to do PFPT\n\nExclusion criteria (CPPS):\n\n1. Nerve-injury related pelvic pain (history of \u002Fspinal cord injury, severe lumbosacral disorder (radiculopathy, spinal stenosis) or other neurological disease affecting pain in the pelvic region(Multiple sclerosis, Alzheimer's, Parkinsons disease)\n2. Acute prostatitis or any acute infection of the pelvic region\n3. History of pelvic trauma","MALE","40 Years",{"count":101,"type":22},186,[25],"The purpose of this study to perform a randomized, sham controlled analysis of the effectiveness of both fSWT and rWT in the relief of erectile dysfunction and chronic pelvic pain syndrome.",[105,106,107,33,31,108,109],"Erectile Dysfunction Due to Arterial Insufficiency","Erectile Dysfunction","Erectile Dysfunction Due to Arterial Disease","Erectile Dysfunction Following Radical Prostatectomy","Erectile Dysfunction Following Radiation Therapy",[111,112,79],"shockwave","radial wave",{"date":82,"type":39},{"date":115,"type":39},"2023-09-19",{"date":117,"type":22},"2026-06",{"name":119,"class":46},"The Cleveland Clinic",{"id":121,"slug":122,"hasResults":11,"nctId":123,"briefTitle":124,"officialTitle":125,"acronym":4,"eligibilityCriteria":126,"healthyVolunteers":11,"sex":98,"minAge":18,"maxAge":127,"enrollmentInfo":128,"targetDuration":4,"studyType":23,"phases":130,"briefSummary":131,"conditions":132,"keywords":4,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":133,"lastUpdatePostDateStruct":134,"startDateStruct":136,"completionDateStruct":138,"leadSponsor":140,"locationsCount":89},"100538218","tavns-improves-the-symptoms-of-patients-with-moderate-to-severe-cpcpps-100538218","NCT06287970","TaVNS Improves the Symptoms of Patients With Moderate to Severe CP\u002FCPPS","Effect of Transcutaneous Auricular Vagus Nerve Stimulation on Moderate to Severe Chronic Prostatitis\u002FChronic Pelvic Pain Syndrome (TASC-P Trial): a Randomized, Sham Controlled Trial.","Inclusion Criteria:\n\n* Consistent with the diagnostic criteria of CP\u002FCPPS of EAU or CAU, the clinical manifestations were recurrent and persistent prostate pain accompanied by abnormal urination and psychiatric symptoms, without infection or other obvious pathological conditions. The pain symptoms were mainly manifested as pain in the surrounding tissues centered on the prostate, and pain, swelling or discomfort in the scrotum, testis, lower abdomen, perineum, lumbosacral area, and medial thigh. Abnormal urination was characterized by frequent urination, urgent urination, urination pain, urethral burning, residual urination or white discharge from the urethra at the end of urination or defecation in the morning. The neuropsychiatric symptoms included dizziness and tinnitus, insomnia and dreams, anxiety and depression, and even impotence, premature ejaculation, and spermatorrhea. Symptoms lasting more than 3 months in the last six months\n* 18 ≤ Age ≤ 50 years old\n* NIH-CPSI ≥15 (patients with moderate to severe CP\u002FCPPS)\n* Signed informed consent and voluntarily participated in the trial\n\nExclusion Criteria:\n\n* Patients with other diseases that cause urinary symptoms were excluded: Such as benign prostatic hyperplasia, testicular and epididymal and spermatic cord diseases, overactive bladder, neurogenic bladder, interstitial cystitis, glandular cystitis, sexually transmitted diseases, bladder tumors such as carcinoma in situ, prostate cancer, urinary male reproductive system tuberculosis, anorectal diseases, lumbar diseases, central and peripheral neuropathy, etc\n* Patients with severe diseases of the heart, liver, kidney, hematopoietic system and poor nutritional status\n* Patients with severe mental and emotional disorders, who were unable to cooperate with the study\n* Patients who have been treated with CP\u002FCPPS regimen in the past 4 weeks","50 Years",{"count":129,"type":22},68,[25],"This trial aims to evaluate the efficacy and safety of transcutaneous auricular vagus nerve stimulation (taVNS) for moderate to severe chronic prostatitis\u002Fchronic pelvic pain syndrome (CP\u002FCPPS). This study is a prospective, randomized, controlled trial. A total of 68 patients with CP\u002FCPPS will be recruited. After baseline assessment, the patients will be randomized into taVNS group (n = 34) and sham-taVNS group (n = 34). The intervention of two group will last for 4 weeks with a 8-week follow-up period after the treatment. The National Institutes of Health chronic Prostatitis Symptom Score index (NIH-CPSI), International Prostate Symptom Score Scale (IPSS), European quality of Life-5 Dimensions Questionnaire (EQ-5D), self-rating anxiety Scale (SAS) and self-rating depression scale (SDS) will be assessed. The adverse events during the whole study will be recorded detailedly.",[31],"2025-11-22",{"date":135,"type":39},"2025-11-28",{"date":137,"type":39},"2024-03-15",{"date":139,"type":22},"2027-02-18",{"name":141,"class":46},"Jiani Wu",{"id":143,"slug":144,"hasResults":11,"nctId":145,"briefTitle":146,"officialTitle":147,"acronym":4,"eligibilityCriteria":148,"healthyVolunteers":11,"sex":98,"minAge":18,"maxAge":4,"enrollmentInfo":149,"targetDuration":4,"studyType":23,"phases":151,"briefSummary":152,"conditions":153,"keywords":155,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":163,"lastUpdatePostDateStruct":164,"startDateStruct":166,"completionDateStruct":168,"leadSponsor":170,"locationsCount":89},"100524926","effects-of-pelvic-floor-training-in-male-chronic-pelvic-pain-correlation-between-subjective-and-objective-outcomes-100524926","NCT06115083","Effects of Pelvic Floor Training in Male Chronic Pelvic Pain, Correlation Between Subjective and Objective Outcomes","Long Term Effects of Pelvic Floor Re-education in Men With Chronic Pelvic Pain, Using Bio-feedback and Home Training - Subjective Outcomes in Correlation to Objective Measurements of the Lower Urinary Tract and Pelvic Floor","Inclusion Criteria:\n\n* Men over the age of 18, residents in Sweden, diagnosed with Chronic Primary Pelvic Pain Syndrome (CPPPS) according to the International Statistical Classification of Diseases and Related Health Problems (ICD-10) (N41.1 (chronic prostatitis), N41.9 (Inflammatory disease of prostate, unspecified), N50.8F (Chronic Pelvic Pain Syndrome in men)\n\nExclusion Criteria:\n\n* Cancer in the abdomen or pelvic organs (current or previous)\n* Congenital anomalies affecting the pelvic region (Bladder exstrophy, Myelomeningocele etc.)\n* Transsexual male, (i.e. at birth biologically female)\n* Diseases affecting the nerve function to the pelvic and\u002For lower extremities, other disease or ongoing treatment that could have an impact on the outcome of the study.\n* Incapability to participate in testing or follow training instructions due to mental incapacity, language difficulties etc.",{"count":150,"type":22},40,[25],"The goal of this randomized controlled study is to establish the long-term effect of pelvic floor re-education using biofeedback and home training for men with chronic pelvic pain. The main questions it aims to answer are if pelvic floor re-education using bio-feedback and home training will give a long-lasting improvement in symptoms, assessed with a validated symptom score (the National Institute of Health - Chronic Prostatitis Symptom Index) and if an improvement in symptoms can be correlated to objective measurements of pelvic floor function. Participants will be asked to do pelvic floor exercises daily during six months with additional sessions of bio-feedback training. The control group will have no changes in their on-going treatment for their chronic pelvic pain and will be offered to enter the treatment group after six months.",[33,67,31,154],"Pelvic Floor; Relaxation",[156,157,158,159,160,161,162],"Chronic pelvic pain syndrome","Chronic prostatitis with chronic pelvic pain syndrome","Chronic prostatitis","Pelvic floor muscles","Urodynamics","Physiotherapy","Bio-feedback","2024-04-12",{"date":165,"type":39},"2024-04-16",{"date":167,"type":39},"2023-12-01",{"date":169,"type":22},"2026-12",{"name":171,"class":172},"Region Stockholm","OTHER_GOV"]